Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies. (APRICOT - Anakinra for Pustular psoriasis: Response in a Controlled Trial)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary)
Indications Palmoplantar pustulosis
Focus Proof of concept; Therapeutic Use
Acronyms APRICOT

Most Recent Events

19 Aug 2021 Primary endpoint has not been met. (Palmoplantar Pustulosis Psoriasis Area and SeverityIndex (PPPASI) at 8 weeks), as per Results published in the British Journal of Dermatology
19 Aug 2021 Results published in the British Journal of Dermatology
05 Aug 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight